NasdaqCM:BLFSLife Sciences
Assessing BioLife Solutions (BLFS) Valuation After Refocus On Higher Margin Cell Processing Business
Why BioLife Solutions stock is on investors’ radar
BioLife Solutions (BLFS) has drawn fresh attention after refocusing on higher-margin cell-processing products and selling its evo Cold Chain business, a move that left the company with over US$125 million in cash.
This shift, together with its role supplying tools for cell and gene therapies, is now central to how investors are thinking about BioLife Solutions, its risk profile, and its potential paths for capital deployment.
See our latest...